tiprankstipranks
Advertisement
Advertisement

CH:MOLN Stock Latest News

Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
RatingsMolecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
7d ago
MOLN
Molecular Partners publishes MP0317 clinical data in Nature Cancer
PremiumThe Fly
Molecular Partners publishes MP0317 clinical data in Nature Cancer
19d ago
MOLN
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
PremiumRatings
Molecular Partners: Unmodeled Upside from MP0632 AND-Gate T Cell Engager Supports Buy Rating and $13 Target
28d ago
MOLN
Molecular Partners announces presentation of preclinical data at AACR
PremiumThe Fly
Molecular Partners announces presentation of preclinical data at AACR
1M ago
MOLN
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
PremiumRatings
Molecular Partners: Strong Cash Runway and Pipeline Catalysts Support DCF‑Backed Buy Rating and $13 Target
2M ago
MOLN
Undervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
PremiumRatingsUndervalued Radioligand Leader: Molecular Partners’ Differentiated RadioDARPin Platform Underpins Buy Rating
2M ago
MOLN
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
Premium
Ratings
Buy Recommendation on Molecular Partners: Advancing Radio-DARPin Platform, Strategic Isotope Collaboration, and Cash Runway Through 2028 Underpin Attractive Risk‑Reward
2M ago
MOLN
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
Premium
Ratings
Buy Rating on Molecular Partners: Expanding Radiopharmaceutical Platform, Isotope Partnership, and Flexible DARPin Strategy Support Favorable Risk-Reward
3M ago
MOLN
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
PremiumThe Fly
Molecular Partners enters Radio-DARPin therapeutics pact with Eckert & Ziegler
3M ago
MOLN
Molecular Partners presents first imaging, dosimetry data of MP0712
PremiumThe Fly
Molecular Partners presents first imaging, dosimetry data of MP0712
4M ago
MOLN
Molecular Partners initiated with a Buy at H.C. Wainwright
PremiumThe Fly
Molecular Partners initiated with a Buy at H.C. Wainwright
4M ago
MOLN
Molecular Partners provided update on latest progress, 2026 milestones
PremiumThe Fly
Molecular Partners provided update on latest progress, 2026 milestones
4M ago
MOLN
Molecular Partners forms Scientific Advisory Board
PremiumThe FlyMolecular Partners forms Scientific Advisory Board
5M ago
MOLN
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
Premium
Ratings
Promising Pipeline and Strategic Focus Drive Buy Rating for Molecular Partners
5M ago
MOLN
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
Premium
The Fly
Molecular Partners price target lowered to CHF 3 from CHF 3.50 at JPMorgan
5M ago
MOLN
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
PremiumThe Fly
Molecular Partners price target lowered to $3.75 from $4 at JPMorgan
5M ago
MOLN
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
PremiumThe Fly
Molecular Partners presents updated data from Phase 1/2a trial of MP0533
5M ago
MOLN
Buy Rating for Molecular Partners: Innovative Pipeline and Promising SCLC Advancements
PremiumRatings
Buy Rating for Molecular Partners: Innovative Pipeline and Promising SCLC Advancements
6M ago
MOLN
Molecular Partners presents new MP0712 data
PremiumThe Fly
Molecular Partners presents new MP0712 data
6M ago
MOLN
Molecular Partners: Promising Pipeline and Strategic Partnerships Justify Buy Rating
PremiumRatingsMolecular Partners: Promising Pipeline and Strategic Partnerships Justify Buy Rating
7M ago
MOLN
Molecular Partners price target lowered to $4 from $4.50 at JPMorgan
Premium
The Fly
Molecular Partners price target lowered to $4 from $4.50 at JPMorgan
9M ago
MOLN
Molecular Partners: Promising Pipeline and Financial Stability Justify Buy Rating Despite IND Delay
Premium
Ratings
Molecular Partners: Promising Pipeline and Financial Stability Justify Buy Rating Despite IND Delay
9M ago
MOLN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >